ROCKVILLE, Md., April 30, 2015 /PRNewswire-USNewswire/ — Lung cancer impacts the lives of millions of people worldwide. In nearly 40 percent of people diagnosed with lung cancer, it has metastasized, or spread to other areas of the body, making it difficult to treat.  Immunotherapy is a type of therapy that uses the body’s own immune […]

(Reuters Health) – Group therapy may work as well as medication to help keep depression from returning for patients who have already taken drugs to control symptoms, a British study suggests.   Researchers studied what’s known as mindfulness-based cognitive therapy, a combination of group counseling sessions and meditation exercises. For people with a history of […]

If your job is chock full of challenging thinking tasks, your brain may be getting a positive boost that will help prevent memory loss and thinking decline later in life, according to a new study. Adding to an already robust catalog of research showing that thinking-related challenges are like exercise for the brain, the latest […]

Nutra Pharma Has Announced That They Have Received Notification of the Acceptance of Nyloxin® by the China International Exchange and Promotive Association for Medical and Healthcare (CPAM) CORAL SPRINGS, FL–(Marketwired – Apr 30, 2015) – Nutra Pharma Corporation (OTC: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), […]

SAN DIEGO, April 30, 2015 /PRNewswire/ — Tamir Biotechnology, a leading developer of RNA modulating drugs, announced today an update on its Ebola antiviral therapy program. Clinical ProgressOne of Tamir’s leading candidates, TMR004, is currently being evaluated and considered by a number of clinicians on the frontline of the battle against Ebola. During the first quarter […]

(Reuters) – Amgen Inc’s skin cancer immunotherapy showed enough efficacy in the treatment of melanoma to be given marketing approval, an independent advisory panel to the U.S. Food and Drug Administration said on Wednesday. The panel voted 22-1 supporting an approval for the therapy, talimogene laherparepvec or “T-Vec”, an engineered virus that kills cancer cells […]

Two days after the U.S. Food & Drug Administration signaled it might quash Amgen Inc.’s attempt to usher in a whole new class of virus-based cancer drugs, an advisory panel for the agency voted “yes” on the question of whether the company’s experimental melanoma treatment, talimogene laherparepvec (T-VEC), has a favorable enough risk-benefit profile for approval. […]

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing and review the supplemental Biologics License Application (sBLA) for Opdivo (nivolumab) for the treatment of previously untreated patients with unresectable or metastatic melanoma. The FDA also granted Priority Review for this application. The projected FDA […]

(Reuters) – U.S. regulators are to fast-track the review of a new use of AstraZeneca’s heart drug Brilinta, meaning it could get the green light in the third quarter to be given to patients with a history of heart attacks. The drugmaker said on Wednesday the decision by the Food and Drug Administration (FDA) reflected […]

CAMBRDIGE, Mass. – Celgene Corporation (CELG) has struck two deals with other pharmaceutical companies with a combined value of $110 million to advance its oncology platform, continuing the cancer drugmaking company’s deal making trend to advance its oncology pipeline. Today Celgene announced it entered into an $80 million agreement with Agios Pharmaceuticals (AGIO) to develop […]